← All trials
NCT05166031
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Apr 30, 2021
- Completion date
- Oct 18, 2021
- First posted
- Dec 21, 2021
- Last posted
- Dec 21, 2021
- Enrollment
- —
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fidec CorporationLead sponsor
- Bill and Melinda Gates FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.